user

5-YEAR OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL IN MULTIPLE MYELOMA BY LINE OF TREATMENT FROM THE FRENCH HEMATOLOGIC MALIGNANCY REGISTRY

被引：1
|
作者：
Mounier, M. [1 ]
Gauthier, S. [1 ]
Mayandi [2 ]
Troussard, X. [3 ]
Monnereau, A. [4 ]
Guilhaume, C. [5 ]
Suzan, F. [6 ]
Blachier-Poisson, C. [5 ]
Despiegel, N. [5 ]
机构：
[1] Univ Bourgogne, Dijon, France
[2] Ctr Hosp Univ Dijon, Dijon, France
[3] CHU Caen, Caen, France
[4] Inst Bergonie, Bordeaux, France
[5] Amgen France, Paris, France
[6] Amgen Europe GmbH, Zug, Switzerland
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.09.2374
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN297
引用
收藏
页码：A762 / A762
页数：1
相关论文
共 50 条
  • [21] Detecting Overall Survival Benefit Derived From Survival Postprogression Rather Than Progression-Free Survival
    Morita, Satoshi
    Sakamaki, Kentaro
    Yin, Guosheng
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2015, 107 (08)
  • [22] Second Autologous Stem Cell Transplantation as Salvage Therapy for Multiple Myeloma: Impact on Progression-Free and Overall Survival
    Jimenez-Zepeda, Victor H.
    Mikhael, Joseph
    Winter, Andrew
    Franke, Norman
    Masih-Khan, Esther
    Trudel, Suzanne
    Chen, Christine
    Kukreti, Vishal
    Reece, Donna E.
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012, 18 (05) : 773 - 779
  • [23] Serological Response to Vaccination after Autologous Transplantation for Multiple Myeloma Is Associated with Improved Progression-Free and Overall Survival
    Merz, Almuth M. A.
    Merz, Maximilian
    Zhang, Yali
    Stecklein, Kathryn
    Pleskow, Jordan
    Chen, George L.
    Buck, Dennis A.
    Mohammadpour, Hemn
    Herr, Megan M.
    Elshoury, Amro
    Hillengass, Jens
    McCarthy, Philip L.
    Hahn, Theresa
    [J]. TRANSPLANTATION AND CELLULAR THERAPY, 2021, 27 (03): : 245.e1 - 245.e8
  • [24] KIR genotype is associated with progression-free and overall survival following autologous stem cell transplantation for multiple myeloma
    Gabriel, I.
    Sargent, R.
    De Lavallade, H.
    Szydlo, R.
    Apperley, J.
    Khoder, A.
    Alsuliman, A.
    Marin, D.
    Foroni, L.
    Davis, J.
    Giles, C.
    Kanfer, E.
    Rahemtulla, A.
    Rezvani, K.
    [J]. BONE MARROW TRANSPLANTATION, 2010, 45 : S148 - S149
  • [25] Progression-free survival as a surrogate for overall survival in first-line chemotherapy for advanced pancreatic cancer
    Hamada, Tsuyoshi
    Nakai, Yousuke
    Isayama, Hiroyuki
    Yasunaga, Hideo
    Matsui, Hiroki
    Takahara, Naminatsu
    Mizuno, Suguru
    Kogure, Hirofumi
    Matsubara, Saburo
    Yamamoto, Natsuyo
    Tada, Minoru
    Koike, Kazuhiko
    [J]. EUROPEAN JOURNAL OF CANCER, 2016, 65 : 11 - 20
  • [26] Relationship between Treatment Effects on Progression-Free Survival and Overall Survival in Multiple Myeloma: A Systematic Review and Meta-Analysis of Published Clinical Trial Data
    Cartier, Shannon
    Zhang, Bin
    Rosen, Virginia M.
    Zarotsky, Victoria
    Bartlett, J. Blake
    Mukhopadhyay, Pralay
    Wagner, Samuel
    Davis, Catherine
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2015, 38 (03) : 88 - 94
  • [27] Prediction of 5-year overall survival of diffuse large B-cell lymphoma on the pola-R-CHP regimen based on 2-year event-free survival and progression-free survival
    Zhang, Wan-Ru
    Liu, Xin
    Zhong, Qiu-Zi
    Wu, Tao
    Yang, Yong
    Chen, Bo
    Jing, Hao
    Tang, Yuan
    Jin, Jing
    Liu, Yue-Ping
    Song, Yong-Wen
    Fang, Hui
    Lu, Ning-Ning
    Li, Ning
    Zhai, Yi-Rui
    Zhang, Wen-Wen
    Wang, Shu-Lian
    Chen, Fan
    Yin, Lin
    Qi, Shu-Nan
    Li, Ye-Xiong
    [J]. CANCER MEDICINE, 2024, 13 (01):
  • [28] Investigation of the Association Between Treatment Effects On Progression Free Survival and Overall Survival in Multiple Myeloma Using Data From Published Literature
    Zhang, Bin
    Cartier, Shannon
    Rosen, Virginia
    Teitelbaum, April
    Zhang, Ying
    Bartlett, Blake J.
    Kroog, Glenn
    Mukhopadhyay, Pralay
    Wagner, Samuel
    [J]. BLOOD, 2012, 120 (21)
  • [29] Therapy of recurrent and refractory multiple Myeloma Isatuximab improves progression-free Survival
    Ruedesheim, Sabine M.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (7-8) : 397 - 397
  • [30] Development of a Prognostic Model That Predicts 3-and 5-Year Overall Survival in Multiple Myeloma Using the Connect® MM Patient Registry
    Terebelo, Howard R.
    Abonour, Rafat
    Gasparetto, Cristina J.
    Toomey, Kathleen
    Durie, Brian G. M.
    Hardin, James W.
    Jagannath, Sundar
    Wagner, Lynne
    Narang, Mohit
    Srinivasan, Shankar
    Yue, Lihua
    Zafar, Faiza
    Kitali, Amani
    Agarwal, Amit
    Rifkin, Robert M.
    [J]. BLOOD, 2017, 130
12345